Histone modifications in drug-resistant cancers: From a cancer stem cell and immune evasion perspective

被引：0
|
作者：
Ming Li Jin
Kwang Won Jeong
机构：
[1] Gachon University,Gachon Research Institute of Pharmaceutical Sciences, College of Pharmacy
来源：
Experimental & Molecular Medicine | 2023年 / 55卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The development and immune evasion of cancer stem cells (CSCs) limit the efficacy of currently available anticancer therapies. Recent studies have shown that epigenetic reprogramming regulates the expression of characteristic marker proteins and tumor plasticity associated with cancer cell survival and metastasis in CSCs. CSCs also possess unique mechanisms to evade external attacks by immune cells. Hence, the development of new strategies to restore dysregulated histone modifications to overcome cancer resistance to chemotherapy and immunotherapy has recently attracted attention. Restoring abnormal histone modifications can be an effective anticancer strategy to increase the therapeutic effect of conventional chemotherapeutic and immunotherapeutic drugs by weakening CSCs or by rendering them in a naïve state with increased sensitivity to immune responses. In this review, we summarize recent findings regarding the role of histone modifiers in the development of drug-resistant cancer cells from the perspectives of CSCs and immune evasion. In addition, we discuss attempts to combine currently available histone modification inhibitors with conventional chemotherapy or immunotherapy.
引用
收藏
页码：1333 / 1347
页数：14
相关论文
共 50 条
  • [41] Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines
    Tsurutani, J
    Soda, H
    Oka, M
    Suenaga, M
    Doi, S
    Nakamura, Y
    Nakatomi, K
    Shiozawa, K
    Yamada, Y
    Kamihira, S
    Kohno, S
    INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (02) : 238 - 242
  • [42] Fenofibrate impairs pro-tumorigenic potential of cancer stem cell-like cells within drug-resistant prostate cancer cell populations
    Wrobel, T.
    Karnas, E.
    Catapano, J.
    Luty, M.
    Piwowarczyk, K.
    Zuba-Surma, E.
    Ryszawy, D.
    Czyz, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [43] Cancer Stem Cell Marker CD44 Plays Multiple Key Roles in Human Cancers: Immune Suppression/Evasion, Drug Resistance, Epithelial-Mesenchymal Transition, and Metastasis
    Dzobo, Kevin
    Sinkala, Musalula
    OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2021, 25 (05) : 313 - 332
  • [44] The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines
    Batova, A
    Shao, LE
    Diccianni, MB
    Yu, AL
    Tanaka, T
    Rephaeli, A
    Nudelman, A
    Yu, J
    BLOOD, 2002, 100 (09) : 3319 - 3324
  • [45] FL118, a novel survivin inhibitor, wins the battle against drug-resistant and metastatic lung cancers through inhibition of cancer stem cell-like properties
    Wang, Jin
    Liu, Zhantao
    Zhang, Dandan
    Liu, Ranran
    Lin, Qian
    Liu, Jia
    Yang, Zhihong
    Ma, Qingxia
    Sun, Dantong
    Zhou, Xin
    Jiang, Guohui
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (08): : 3676 - 3686
  • [46] A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: A gene therapy approach for drug-resistant cancers
    Seth, P
    Katayose, D
    Li, ZW
    Kim, M
    Wersto, R
    Craig, C
    Shanmugam, N
    Ohri, E
    Mudahar, B
    Rakkar, ANS
    Kodali, P
    Cowan, K
    CANCER GENE THERAPY, 1997, 4 (06) : 383 - 390
  • [47] Cancer cell theranostics rapidly detects and destroys drug-resistant tumors in vivo
    Lapotko, Dmitri
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [48] Alterations in Nuclear Pore Architecture Allow Cancer Cell Entry into or Exit from Drug-Resistant Dormancy
    Kinoshita, Yayoi
    Kalir, Tamara
    Rahaman, Jamal
    Dottino, Peter
    Kohtz, D. Stave
    AMERICAN JOURNAL OF PATHOLOGY, 2012, 180 (01): : 375 - 389
  • [49] Altered Histone Modifications and Their Regulating Enzymes in Fulvestrant Resistant Breast Cancer Cell Line In Vitro
    Elsheikh, S. E.
    Green, A. R.
    McClelland, R. A.
    Hutcheson, I. R.
    Gee, J. M.
    Nicholson, R. I.
    Ellis, I. O.
    LABORATORY INVESTIGATION, 2009, 89 : 38A - 39A
  • [50] Altered Histone Modifications and Their Regulating Enzymes in Fulvestrant Resistant Breast Cancer Cell Line In Vitro
    Elsheikh, S. E.
    Green, A. R.
    McClelland, R. A.
    Hutcheson, I. R.
    Gee, J. M.
    Nicholson, R. I.
    Ellis, I. O.
    MODERN PATHOLOGY, 2009, 22 : 38A - 39A
12345